What is Zymeworks?
Founded in 2003 and headquartered in Vancouver, BC, Zymeworks is at the forefront of biopharmaceutical innovation. The company is dedicated to the research and development of advanced, multifunctional biotherapeutics designed to address significant unmet medical needs. Its clinical-stage operations suggest a company transitioning from early-stage research to late-stage development and potential commercialization, leveraging substantial financial backing to advance its pipeline.
How much funding has Zymeworks raised?
Zymeworks has raised a total of $819.8M across 13 funding rounds:
Multiple Rounds
$22.3M
Multiple Rounds
$34.4M
Series A
$61.5M
Stock Offering
$63.6M
Stock Offering
$97.8M
Stock Offering
$201.3M
Stock Offering
$320.8M
Unspecified (2014): $1M supported by Undisclosed
Share Placement (2014): $17.3M featuring Undisclosed
Corporate Investment (2014): $4M backed by Fonds de Solidarité FTQ
Unspecified (2015): $8.6M with participation from Undisclosed
Unspecified (2015): $24M led by Undisclosed
Unspecified (2015): $1.8M supported by Undisclosed
Series A (2016): $61.5M featuring Fonds de Solidarité FTQ, Lumira Capital, Perceptive Advisors, Teralys Capital, Merlin Nexus, Northleaf Venture Catalyst Fund, Brace Pharma Capital, CTI Life Sciences Fund, Eli Lilly & Company, Celgene, and BDC Capital
Stock Issuance/Offering (2017): $63.6M backed by Undisclosed
Stock Issuance/Offering (2018): $97.8M with participation from Undisclosed
Stock Issuance/Offering (2019): $201.3M led by Undisclosed
Stock Issuance/Offering (2020): $320.8M supported by Undisclosed
Key Investors in Zymeworks
Fonds de Solidarité FTQ
Founded in 1983, Fonds de Solidarité FTQ is a private equity and venture capital firm specializing in investments in start-ups, early ventures, mergers, and business acquisitions, located in Canada.
Lumira Capital
Lumira Capital is a venture capital firm that likely focuses on investments in the life sciences and healthcare sectors, given its domain.
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
What's next for Zymeworks?
The substantial enterprise-level funding Zymeworks has attracted indicates a strong market confidence in its therapeutic platforms and strategic direction. This capital infusion is expected to fuel further clinical trials, expand research and development capabilities, and potentially support manufacturing and commercialization efforts. The company's focus on next-generation biotherapeutics positions it for significant growth and impact within the biopharmaceutical sector, aiming to bring innovative treatments to patients worldwide.
See full Zymeworks company page
